SOLVE FSHD has awarded approximately USD 571,000 across two projects through its 2025 Request for Proposals, directing the funds toward biomarker validation and clinical outcome measure development in facioscapulohumeral muscular dystrophy. The awards were selected from an international applicant pool following review by external experts.
The first project, titled "PERSPECTIVE - Longitudinal validation of blood-derived biomarkers in FSHD," is led by Prof. Nicol Voermans at Radboud University Medical Center. The second, "Validation of a New Clinical Outcome Measure for Facioscapulohumeral Muscular Dystrophy: The North Star Assessment for FSHD," is led by Prof. Dr. Giorgio Tasca and Dr. Robert Muni Lofra at Newcastle University. Neither project appears to be an interventional therapeutic trial; both are oriented toward validating measurement tools intended for use in future FSHD clinical trials.
The funding reflects a continued philanthropic emphasis on trial-enabling infrastructure in a disease area where the absence of accepted biomarkers and sensitive outcome measures has been a recognized barrier to clinical development. SOLVE FSHD has framed the awards as contributions toward a shared toolkit for academic and industry trial sponsors, with regulatory-aligned endpoint development cited as an explicit objective.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Spot something wrong? Report an issue with this article